Invesco Ltd. Sells 1,625,047 Shares of Danaher Corporation $DHR

Invesco Ltd. cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 34.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,083,531 shares of the conglomerate’s stock after selling 1,625,047 shares during the period. Invesco Ltd. owned about 0.43% of Danaher worth $609,121,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Ceredex Value Advisors LLC lifted its holdings in Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after acquiring an additional 3,862 shares in the last quarter. Chicago Capital LLC raised its stake in shares of Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after purchasing an additional 1,391 shares during the period. Weitz Investment Management Inc. boosted its position in Danaher by 6.1% during the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after acquiring an additional 30,300 shares during the last quarter. UniSuper Management Pty Ltd grew its position in Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Finally, Nvwm LLC grew its holdings in shares of Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after acquiring an additional 1,204 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. TD Cowen increased their price target on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Redburn Partners set a $220.00 target price on Danaher in a research note on Wednesday, October 8th. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Finally, Barclays lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Twenty research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.75.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 over the last 90 days. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $227.13 on Friday. The stock has a market capitalization of $160.43 billion, a PE ratio of 46.83, a P/E/G ratio of 4.43 and a beta of 0.89. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The business has a fifty day moving average price of $215.40 and a two-hundred day moving average price of $204.10.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.71 earnings per share. As a group, equities analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.